{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T04:19:16Z","timestamp":1783743556602,"version":"3.55.0"},"reference-count":44,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,26]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Fidanacogene elaparvovec is a single-dose gene therapy designed to express the high-activity factor IX (FIX) variant FIX-R338L. Participants (N = 15) with FIX activity of \u22642% were dosed with 5 \u00d7 1011 vector genomes per kilogram infusion of fidanacogene elaparvovec and completed the 1-year dosing trial. After the initial 52 weeks, participants could enroll in long-term follow-up (LTFU) for 5 additional years. This report includes final safety and efficacy data of the LTFU trial through 6 years after gene therapy, with additional patient-reported outcomes (PROs). Of 14 participants enrolled in the LTFU, 11 completed 6 years of follow-up. During years 2 to 6, 9 serious adverse events were reported in 4 participants (28.6%); none were considered treatment-related or resulted in study discontinuation or death. Eight participants had increased alanine aminotransferase levels, and 3 of 8 also had increased aspartate aminotransferase levels; none received corticosteroids. No liver masses, malignancies, thrombotic events, or FIX inhibitors were reported. FIX activity was maintained, with a mean FIX activity of 24.7% at year 2 (n = 14) and 26.1% at year 6 (n = 11). Mean treated annualized bleeding rates remained lower than 1.0 (median, 0.0) during each year of follow-up. Ten participants (71%) had no treated bleeding events. None of the 14 enrolled participants resumed FIX prophylaxis. Improvements relative to before gene therapy in PROs and target joints were observed over the duration of follow-up. Overall, fidanacogene elaparvovec exhibited a favorable safety profile, sustained efficacy, and improved PROs for up to 6 years. This trial is registered at www.clinicaltrials.gov as NCT03307980.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025019174","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T22:08:02Z","timestamp":1771970882000},"page":"3517-3526","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Safety, efficacy, and patient-reported outcomes 6 years after fidanacogene elaparvovec in adults with hemophilia B"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6772-4140","authenticated-orcid":false,"given":"Benjamin J.","family":"Samelson-Jones","sequence":"first","affiliation":[{"name":"1Division of Hematology, Children\u2019s Hospital of Philadelphia, Philadelphia, PA"},{"name":"2Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2975-807X","authenticated-orcid":false,"given":"John E. J.","family":"Rasko","sequence":"additional","affiliation":[{"name":"3University of Sydney, Central Clinical School, Faculty of Medicine and Health, Sydney, NSW, Australia"},{"name":"4Department of Cell and Molecular Therapies, Royal Prince Alfred Hospital, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4282-0632","authenticated-orcid":false,"given":"Jonathan M.","family":"Ducore","sequence":"additional","affiliation":[{"name":"5Hemophilia Treatment Center, University of California Davis, Sacramento, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3421-0925","authenticated-orcid":false,"given":"Catherine E.","family":"McGuinn","sequence":"additional","affiliation":[{"name":"6Division of Pediatric Hematology\/Oncology, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9763-1559","authenticated-orcid":false,"given":"Lindsey A.","family":"George","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Children\u2019s Hospital of Philadelphia, Philadelphia, PA"},{"name":"2Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5926-0478","authenticated-orcid":false,"given":"Sylvia","family":"von Mackensen","sequence":"additional","affiliation":[{"name":"7Department of Medical Psychology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Borgonuovo","sequence":"additional","affiliation":[{"name":"8Pfizer Srl, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4166-4385","authenticated-orcid":false,"given":"Delphine","family":"Agathon","sequence":"additional","affiliation":[{"name":"9Pfizer Inc, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne","family":"Smith","sequence":"additional","affiliation":[{"name":"10Pfizer Inc, Collegeville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2642-4827","authenticated-orcid":false,"given":"Lisa J.","family":"Wilcox","sequence":"additional","affiliation":[{"name":"11Pfizer Inc, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Biondo","sequence":"additional","affiliation":[{"name":"12Pfizer Srl, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7631-3343","authenticated-orcid":false,"given":"Frank","family":"Plonski","sequence":"additional","affiliation":[{"name":"10Pfizer Inc, Collegeville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"issue":"1","key":"2026052610375158200_bib1","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/hae.70113","article-title":"The WFH guidelines for the management of haemophilia: AAV gene therapy, 2025","volume":"32","author":"Pierce","year":"2026","journal-title":"Haemophilia"},{"issue":"6","key":"2026052610375158200_bib2","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/hae.13327","article-title":"Monitoring joint health in haemophilia: factors associated with deterioration","volume":"23","author":"Kuijlaars","year":"2017","journal-title":"Haemophilia"},{"issue":"9","key":"2026052610375158200_bib3","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1111\/jth.15444","article-title":"Hemophilic arthropathy: current knowledge and future perspectives","volume":"19","author":"Gualtierotti","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2026052610375158200_bib4","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/hae.12239","article-title":"Haemophilia Experiences, Results and Opportunities (HERO) study: survey methodology and population demographics","volume":"20","author":"Forsyth","year":"2014","journal-title":"Haemophilia"},{"key":"2026052610375158200_bib5","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.2147\/PPA.S87659","article-title":"Associations of quality of life, pain, and self-reported arthritis with age, employment, bleed rate, and utilization of hemophilia treatment center and health care provider services: results in adults with hemophilia in the HERO study","volume":"9","author":"Forsyth","year":"2015","journal-title":"Patient Prefer Adherence"},{"issue":"suppl 1","key":"2026052610375158200_bib6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/ejh.13027","article-title":"Assessments of pain, functional impairment, anxiety, and depression in US adults with hemophilia across patient-reported outcome instruments in the Pain, Functional Impairment, and Quality of Life (P-FiQ) study","volume":"100","author":"Buckner","year":"2018","journal-title":"Eur J Haematol"},{"issue":"10","key":"2026052610375158200_bib7","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.jpain.2021.03.157","article-title":"Prevalence and interference of chronic pain among people with hemophilia: a systematic review and meta-analysis","volume":"22","author":"Paredes","year":"2021","journal-title":"J Pain"},{"issue":"2","key":"2026052610375158200_bib8","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1365-2516.2006.01203.x","article-title":"Pain and functional limitations in patients with severe haemophilia","volume":"12","author":"van Genderen","year":"2006","journal-title":"Haemophilia"},{"issue":"5","key":"2026052610375158200_bib9","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1111\/hae.13596","article-title":"Real-world comparative analysis of bleeding complications and health-related quality of life in patients with haemophilia A and haemophilia B","volume":"24","author":"Booth","year":"2018","journal-title":"Haemophilia"},{"issue":"1","key":"2026052610375158200_bib10","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13023-021-01774-9","article-title":"Clinical, humanistic, and economic burden of severe hemophilia B in the United States: results from the CHESS US and CHESS US+ population surveys","volume":"16","author":"Burke","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"2026052610375158200_bib11","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/hae.14525","article-title":"Quality of life in a large multinational haemophilia B cohort (the B-Natural study) \u2013 unmet needs remain","volume":"28","author":"Berntorp","year":"2022","journal-title":"Haemophilia"},{"issue":"4","key":"2026052610375158200_bib12","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/hae.14759","article-title":"No difference in quality of life between persons with severe haemophilia A and B","volume":"29","author":"Kihlberg","year":"2023","journal-title":"Haemophilia"},{"issue":"1","key":"2026052610375158200_bib13","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s13023-022-02301-0","article-title":"Health-related quality of life, direct medical and societal costs among children with moderate or severe haemophilia in Europe: multivariable models of the CHESS-PAEDs study","volume":"17","author":"Rodriguez-Santana","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"2026052610375158200_bib14","volume-title":"National Institutes of Health and Care Excellence","year":"2025"},{"issue":"11","key":"2026052610375158200_bib15","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/jth.12672","article-title":"Definitions in hemophilia: communication from the SSC of the ISTH","volume":"12","author":"Blanchette","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"suppl 6","key":"2026052610375158200_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"issue":"1","key":"2026052610375158200_bib17","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/hae.14675","article-title":"Association of factor expression levels with annual bleeding rate in people with haemophilia B","volume":"29","author":"Burke","year":"2023","journal-title":"Haemophilia"},{"issue":"12","key":"2026052610375158200_bib18","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa2302982","article-title":"Gene therapy with fidanacogene elaparvovec in adults with hemophilia B","volume":"391","author":"Cuker","year":"2024","journal-title":"N Engl J Med"},{"issue":"23","key":"2026052610375158200_bib19","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B gene therapy with a high-specific-activity factor IX variant","volume":"377","author":"George","year":"2017","journal-title":"N Engl J Med"},{"issue":"15","key":"2026052610375158200_bib20","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1056\/NEJMoa2307159","article-title":"Fidanacogene elaparvovec for hemophilia B - a multiyear follow-up study","volume":"392","author":"Rasko","year":"2025","journal-title":"N Engl J Med"},{"issue":"8","key":"2026052610375158200_bib21","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with etranacogene dezaparvovec for hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N Engl J Med"},{"key":"2026052610375158200_bib22","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1056\/NEJMoa2514332","article-title":"Final analysis of a study of etranacogene dezaparvovec for hemophilia B","volume":"394","author":"Pipe","year":"2025","journal-title":"N Engl J Med"},{"issue":"14","key":"2026052610375158200_bib23","doi-asserted-by":"crossref","first-page":"e128683","DOI":"10.1172\/jci.insight.128683","article-title":"Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity","volume":"5","author":"Samelson-Jones","year":"2019","journal-title":"JCI Insight"},{"issue":"11","key":"2026052610375158200_bib24","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1016\/j.ymthe.2023.10.015","article-title":"Lethal immunotoxicity in high-dose systemic AAV therapy","volume":"31","author":"Duan","year":"2023","journal-title":"Mol Ther"},{"key":"2026052610375158200_bib25","doi-asserted-by":"crossref","first-page":"r1548","DOI":"10.1136\/bmj.r1548","article-title":"Duchenne gene therapy halted after three deaths and company u turn","volume":"390","author":"Taylor","year":"2025","journal-title":"BMJ"},{"issue":"3","key":"2026052610375158200_bib26","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/hae.14977","article-title":"Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: results from the phase III HOPE-B trial 2 years after gene therapy","volume":"30","author":"Itzler","year":"2024","journal-title":"Haemophilia"},{"issue":"6","key":"2026052610375158200_bib27","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/hae.14184","article-title":"Determining meaningful health-related quality-of-life improvement in persons with haemophilia A using the haemophilia quality of life questionnaire for adults (Haem-A-QoL)","volume":"26","author":"von Mackensen","year":"2020","journal-title":"Haemophilia"},{"issue":"5","key":"2026052610375158200_bib28","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/hae.12642","article-title":"Interpreting important health-related quality of life change using the Haem-A-QoL","volume":"21","author":"Wyrwich","year":"2015","journal-title":"Haemophilia"},{"key":"2026052610375158200_bib29","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1477-7525-5-70","article-title":"Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer","volume":"5","author":"Pickard","year":"2007","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"2026052610375158200_bib30","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/hae.14226","article-title":"Assessing the test-retest reliability and smallest detectable change of the haemophilia activities list","volume":"27","author":"Kuijlaars","year":"2021","journal-title":"Haemophilia"},{"issue":"19","key":"2026052610375158200_bib31","doi-asserted-by":"crossref","first-page":"5817","DOI":"10.1182\/bloodadvances.2023010723","article-title":"Residual burden of liver disease after HCV clearance in hemophilia: a word of caution in the era of gene therapy","volume":"7","author":"La Mura","year":"2023","journal-title":"Blood Adv"},{"key":"2026052610375158200_bib32","doi-asserted-by":"crossref","first-page":"10760296221128294","DOI":"10.1177\/10760296221128294","article-title":"Prevalence of non-alcoholic fatty liver disease and associated factors in patients with moderate or severe hemophilia: a multicenter-based study","volume":"28","author":"Shen","year":"2022","journal-title":"Clin Appl Thromb Hemost"},{"key":"2026052610375158200_bib33","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.omtm.2023.08.015","article-title":"Modifying immune responses to adeno-associated virus vectors by capsid engineering","volume":"30","author":"Bentler","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"7","key":"2026052610375158200_bib34","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/j.ymthe.2024.05.033","article-title":"Clinical immunogenicity outcomes from GENEr8-1, a phase 3 study of valoctocogene roxaparvovec, an AAV5-vectored gene therapy for hemophilia A","volume":"32","author":"Long","year":"2024","journal-title":"Mol Ther"},{"issue":"7","key":"2026052610375158200_bib35","doi-asserted-by":"crossref","first-page":"e504","DOI":"10.1016\/S2352-3026(22)00113-2","article-title":"Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial","volume":"9","author":"Xue","year":"2022","journal-title":"Lancet Haematol"},{"issue":"17","key":"2026052610375158200_bib36","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1182\/bloodadvances.2024013150","article-title":"Blood biodistribution and vector shedding of valoctocogene roxaparvovec in people with severe hemophilia A","volume":"8","author":"Agarwal","year":"2024","journal-title":"Blood Adv"},{"issue":"4","key":"2026052610375158200_bib37","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.ymthe.2022.03.004","article-title":"Durability of transgene expression after rAAV gene therapy","volume":"30","author":"Muhuri","year":"2022","journal-title":"Mol Ther"},{"key":"2026052610375158200_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2025.04.045","article-title":"Current clinical applications of AAV-mediated gene therapy","author":"Byrne","year":"2025;33(6):2479-2516","journal-title":"Mol Ther"},{"issue":"5","key":"2026052610375158200_bib39","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/j.ymthe.2025.03.043","article-title":"Gene therapy for hemophilia - from basic science to first approvals of \"one-and-done\" therapies","volume":"33","author":"Herzog","year":"2025","journal-title":"Mol Ther"},{"issue":"4","key":"2026052610375158200_bib40","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/hae.13214","article-title":"Self-reported prevalence, description and management of pain in adults with haemophilia: methods, demographics and results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study","volume":"23","author":"Witkop","year":"2017","journal-title":"Haemophilia"},{"issue":"3","key":"2026052610375158200_bib41","first-page":"398","article-title":"Haemophilia B: impact on patients and economic burden of disease","volume":"106","author":"Gater","year":"2011","journal-title":"Thromb Haemost"},{"issue":"5","key":"2026052610375158200_bib42","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1111\/hae.13548","article-title":"Emotional distress in haemophilia: factors associated with the presence of anxiety and depression symptoms among adults","volume":"24","author":"Pinto","year":"2018","journal-title":"Haemophilia"},{"issue":"8","key":"2026052610375158200_bib43","doi-asserted-by":"crossref","first-page":"e1232","DOI":"10.1016\/S2214-109X(24)00150-5","article-title":"National, regional, and global trends in insufficient physical activity among adults from 2000 to 2022: a pooled analysis of 507 population-based surveys with 5.7 million participants","volume":"12","author":"Strain","year":"2024","journal-title":"Lancet Glob Health"},{"issue":"suppl 1","key":"2026052610375158200_bib44","first-page":"3628-3628","article-title":"Health-related quality of life in adults with hemophilia B after receiving gene therapy with fidanacogene elaparvovec","volume":"142","author":"von Mackensen","year":"2023","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/10\/3517\/2519604\/blooda_adv-2025-019174-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/10\/3517\/2519604\/blooda_adv-2025-019174-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T14:38:03Z","timestamp":1779806283000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/10\/3517\/566833\/Safety-efficacy-and-patient-reported-outcomes-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,5,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025019174","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,26]]},"published":{"date-parts":[[2026,5,15]]}}}